Basel Medical Group (NASDAQ:BMGL) Releases Quarterly Earnings Results

Basel Medical Group (NASDAQ:BMGL) posted its quarterly earnings results on Friday. The company reported $0.00 earnings per share for the quarter, FiscalAI reports. The company had revenue of $3.21 million during the quarter.

Basel Medical Group Stock Up 2.4%

Shares of NASDAQ:BMGL opened at $6.87 on Friday. The stock’s 50-day moving average is $7.44 and its 200-day moving average is $7.76. Basel Medical Group has a 52-week low of $4.60 and a 52-week high of $54.60.

Institutional Trading of Basel Medical Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Basel Medical Group during the third quarter worth about $169,000. Virtu Financial LLC raised its holdings in Basel Medical Group by 108.8% in the 3rd quarter. Virtu Financial LLC now owns 33,786 shares of the company’s stock valued at $61,000 after acquiring an additional 17,608 shares in the last quarter. Finally, Marex Group plc acquired a new position in Basel Medical Group in the 2nd quarter valued at approximately $25,000.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Basel Medical Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Basel Medical Group has an average rating of “Sell”.

Basel Medical Group Company Profile

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.